Treace Medical Concepts Reports First Quarter 2026 Financial Results
Rhea-AI Summary
Treace Medical Concepts (Nasdaq: TMCI) reported Q1 2026 results for the quarter ended March 31, 2026. Revenue was $47.2M (down 10% YoY). Net loss was $18.0M (−$0.28 per share) and adjusted EBITDA was −$5.5M. Cash and marketable securities totaled $51.9M. The company reaffirmed 2026 revenue guidance of $202M–$212M and expects full‑year adjusted EBITDA loss of $4M–$6M, plus a targeted ~50% reduction in cash usage versus 2025.
AI-generated analysis. Not financial advice.
Positive
- Cash and marketable securities of $51.9M as of March 31, 2026
- Reaffirmed full‑year revenue guidance of $202M–$212M for 2026
- Credit facility providing an additional $115M of liquidity subject to conditions
Negative
- Revenue declined 10% YoY to $47.2M in Q1 2026
- Reported net loss $18.0M and adjusted EBITDA loss of $5.5M in Q1
- Guidance reflects continued product and price mix headwinds offsetting case growth
News Market Reaction – TMCI
On the day this news was published, TMCI gained 4.69%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.0% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $144.15M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows mixed moves among medical-device peers (e.g., RXST up ~5%, CTKB down ~9.76%) with no consistent sector direction, suggesting company-specific focus for TMCI.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 27 | Q4 & 2025 earnings | Negative | -11.4% | Reported modest 2025 growth but guided 2026 to flat-to-down revenue with losses. |
| Feb 12 | Earnings date update | Neutral | -2.1% | Rescheduled Q4 and full-year 2025 earnings release and call logistics. |
| Nov 06 | Q3 2025 earnings | Negative | -28.3% | Delivered revenue growth but cut 2025 revenue and EBITDA guidance, citing demand headwinds. |
| Aug 07 | Q2 2025 earnings | Positive | +7.9% | Reported revenue growth, better losses, strong liquidity and maintained 2025 guidance. |
| May 08 | Q1 2025 earnings | Positive | -9.6% | Showed revenue growth and margin strength while reaffirming full‑year 2025 outlook. |
Past earnings releases have often coincided with negative price reactions; average move around earnings-related news is -8.7%, indicating a history of cautious market responses.
Recent earnings history for TMCI shows growing revenue through Q2–Q4 2025 but persistent net losses and guidance resets. Q1 and Q2 2025 reported mid‑ to high‑single‑digit revenue growth and improving Adjusted EBITDA, yet shares frequently traded lower post‑report. By Q3 2025, guidance was cut, and the stock fell sharply. The Q4 2025 release maintained modest growth but again saw a double‑digit decline. Today’s Q1 2026 results, featuring a 10% revenue decline and reiterated 2026 guidance, follow this pattern of earnings as key catalysts.
Historical Comparison
In the past, TMCI earnings headlines produced an average move of -8.7%. This Q1 2026 report, with revenue down and guidance reiterated, fits into that historically cautious setup.
Earnings updates have evolved from 2025 growth with guidance cuts to 2026 expectations of flat-to-down revenue and ongoing Adjusted EBITDA losses, highlighting a shift from expansion to consolidation.
Market Pulse Summary
This announcement highlights a mixed quarter, with Q1 2026 revenue falling to $47.2M (down 10% year over year) and a wider Adjusted EBITDA loss of $(5.5)M, but gross margin holding at 79.3%. Management reaffirmed 2026 revenue guidance of $202M–$212M and targets a ~50% reduction in cash usage versus 2025. Historically, earnings headlines have produced an average move of -8.7%, so investors may watch upcoming quarters for evidence that guidance and cost-control goals remain on track.
Key Terms
adjusted EBITDA financial
credit facility financial
GAAP financial
non-GAAP financial measures financial
AI-generated analysis. Not financial advice.
PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026.
Recent Highlights
- Generated revenue of
$47.2 million in first quarter 2026 compared to$52.6 million in the same period in 2025. - Reported first quarter 2026 net loss of
$(18.0) million and adjusted EBITDA of$(5.5) million in the first quarter 2026. - Cash, cash equivalents, and marketable securities totaled
$51.9 million as of March 31, 2026, representing an increase of$3.5 million from the Company’s balance of$48.4 million as of December 31, 2025, and compares to an increase of approximately$0.4 million in the first quarter of 2025. - Initiated limited market release of SuperBite™ Compression Screw System with successful first commercial cases.
- Broadened global patent portfolio surpassing 130 granted patents in addition to over 200 pending patent applications.
“We are encouraged by the growing demand for our comprehensive portfolio of best-in-class bunion and midfoot correction systems, including our new products, which expand our addressable procedure opportunities across our growing surgeon base,” said John T. Treace, CEO and Chairman of Treace Medical. “In the first quarter, we continued to take market share and grow year-over-year case volumes. We remain focused on driving surgeon adoption of our broadened portfolio and commercializing our 2026 new product launches while advancing a robust pipeline of future product innovations. With continued focus on commercial execution and operational discipline, we believe we are well positioned to drive further share gains and return to stronger growth in the back half of the year.”
First Quarter 2026 Financial Results
Revenue for the first quarter of 2026 was
Gross profit for the first quarter of 2026 was
Total operating expenses were
First quarter 2026 net loss was
Cash, cash equivalents, and marketable securities totaled
2026 Financial Outlook
The Company is reaffirming its full-year 2026 revenue guidance to be in the range of
The Company reiterates its expectation of a loss in Adjusted EBITDA in the range of
The Company reiterates its expectation for a reduction in cash usage of approximately
The Company’s full-year 2026 guidance reflects continued case volume growth, offset by continued headwinds from demand driven product and price mix shift within Treace’s expanded product portfolio.
Webcast and Conference Call Details
Treace will host a conference call today, May 8, 2026, at 8:00 a.m. ET to discuss its first quarter 2026 financial results. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. The live webcast of the conference call will be available on the Investor Relations section of the Company’s website at investors.treace.com. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, this earnings release presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. Non-GAAP financial measures such as Adjusted EBITDA are presented in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management uses non-GAAP financial measures to evaluate the Company’s operating performance and trends, as well as for making planning decisions. The Company believes that Adjusted EBITDA helps to identify underlying trends in the Company’s business that may otherwise be masked by the effect of the income and expenses and other items that it excludes in its calculation of Adjusted EBITDA. Accordingly, the Company believes this non-GAAP financial measure provides useful information to investors and others in understanding and evaluating the Company’s operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by the Company’s management in their financial and operational decision-making. The Company also presents this non-GAAP financial measure because it believes investors, analysts and rating agencies consider it to be a useful metric in measuring the Company’s performance against other companies and its ability to meet its debt service obligations.
There are limitations related to the use of non-GAAP financial measures such as Adjusted EBITDA because they are not prepared in accordance with GAAP, may exclude significant income and expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation between GAAP and non-GAAP results is presented below.
*A reconciliation of Adjusted EBITDA to GAAP net loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.
Forward-Looking Statements
This press release and statements made during the Company’s earnings call contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s: 2026 full-year guidance; anticipated liquidity; 2026 Adjusted EBITDA guidance; expected 2026 cash usage decrease; anticipated return to stronger growth in the second half of the year; expected increase in product adoptions, portfolio utilization and market share; continued execution of commercial and other strategic initiatives; ability to effectively respond to and mitigate the impact of challenges in the current market environment, including in response to increased competition, evolving surgeon and patient preferences for minimally invasive bunion solutions, changes in tariffs and trade policies, protracted government shutdowns, and lower patient demand for elective bunion surgery due to macroeconomic uncertainty and soft consumer sentiment; anticipated future product launches and the timing of such product launches; ability to increase procedure volumes, expand surgeon relationships and utilization rate, and increase procedure penetration and market share; ability to protect and enforce its intellectual property rights, including through its patent infringement and unfair competition suits; success in defending against securities class actions and infringement of its intellectual property by third parties, including its competitors; expected seasonality; ability to leverage investments in its commercial organization and control costs in its organizational structure; anticipated expansion of clinical evidence; the amount and timing of orders for our products from stocking distributors and other customers; and anticipated pace of growth in the foot and ankle market. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 27, 2026. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. The Company’s results for the quarter ended March 31, 2026 are not necessarily indicative of its operating results for any future periods.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty®3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System, and the SpeedMTP® MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide™ patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
| Treace Medical Concepts, Inc. Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | $ | 47,198 | $ | 52,570 | ||||
| Cost of goods sold | 9,791 | 10,677 | ||||||
| Gross profit | 37,407 | 41,893 | ||||||
| Operating expenses | ||||||||
| Sales and marketing | 33,775 | 36,122 | ||||||
| Research and development | 4,622 | 5,562 | ||||||
| General and administrative | 16,177 | 15,791 | ||||||
| Total operating expenses | 54,574 | 57,475 | ||||||
| Loss from operations | (17,167 | ) | (15,582 | ) | ||||
| Interest income | 501 | 841 | ||||||
| Interest expense | (1,570 | ) | (1,311 | ) | ||||
| Other income, net | 275 | 130 | ||||||
| Other non-operating income (expense), net | (794 | ) | (340 | ) | ||||
| Net loss | $ | (17,961 | ) | $ | (15,922 | ) | ||
| Other comprehensive income (loss) | ||||||||
| Unrealized gain (loss) on marketable securities | $ | (98 | ) | $ | (40 | ) | ||
| Comprehensive loss | $ | (18,059 | ) | $ | (15,962 | ) | ||
| Net loss per share, basic and diluted | $ | (0.28 | ) | $ | (0.25 | ) | ||
| Weighted-average shares used in computing net loss per share, basic and diluted | 64,592,681 | 62,661,447 | ||||||
| Treace Medical Concepts, Inc. Balance Sheets (in thousands, except share and per share amounts) (unaudited) | ||||||||
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 9,544 | $ | 10,708 | ||||
| Marketable securities, short-term | 42,310 | 37,659 | ||||||
| Accounts receivable, net of allowance for credit losses of | 30,358 | 42,155 | ||||||
| Inventories | 36,366 | 36,031 | ||||||
| Prepaid expenses and other current assets | 4,893 | 5,501 | ||||||
| Total current assets | 123,471 | 132,054 | ||||||
| Property and equipment, net | 32,063 | 29,752 | ||||||
| Intangible assets, net of accumulated amortization of | 6,887 | 7,125 | ||||||
| Goodwill | 12,815 | 12,815 | ||||||
| Operating lease right-of-use assets | 7,371 | 7,614 | ||||||
| Other non-current assets, net of allowance for credit losses of | 1,495 | 1,221 | ||||||
| Total assets | $ | 184,102 | $ | 190,581 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 13,537 | $ | 6,726 | ||||
| Accrued liabilities | 5,978 | 5,784 | ||||||
| Accrued commissions | 6,755 | 9,365 | ||||||
| Accrued compensation | 5,621 | 6,331 | ||||||
| Other liabilities | 2,600 | 2,429 | ||||||
| Total current liabilities | 34,491 | 30,635 | ||||||
| Long-term debt, net | 55,820 | 55,583 | ||||||
| Operating lease liabilities, net of current portion | 13,551 | 13,982 | ||||||
| Other long-term liabilities | 3,049 | 3,049 | ||||||
| Total liabilities | 106,911 | 103,249 | ||||||
| Commitments and contingencies (Note 7) | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 65 | 64 | ||||||
| Additional paid-in capital | 345,495 | 337,371 | ||||||
| Accumulated deficit | (266,953 | ) | (248,992 | ) | ||||
| Accumulated other comprehensive income (loss) | (26 | ) | 72 | |||||
| Treasury stock, at cost; 248,126 and 165,513 shares as of March 31, 2026 and December 31, 2025, respectively | (1,390 | ) | (1,183 | ) | ||||
| Total stockholders’ equity | 77,191 | 87,332 | ||||||
| Total liabilities and stockholders’ equity | $ | 184,102 | $ | 190,581 | ||||
| Treace Medical Concepts, Inc. Statements of Cash Flows (in thousands) (unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (17,961 | ) | $ | (15,922 | ) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities | ||||||||
| Depreciation and amortization expense | 899 | 2,461 | ||||||
| Provision for allowance for credit losses | 112 | 500 | ||||||
| Share-based compensation expense | 8,034 | 8,693 | ||||||
| Non-cash lease expense | 571 | 578 | ||||||
| Amortization of debt issuance costs | 262 | 74 | ||||||
| Amortization (accretion) of premium (discount) on marketable securities, net | 5 | (77 | ) | |||||
| Other, net | 587 | 187 | ||||||
| Net changes in operating assets and liabilities, net of acquisitions | ||||||||
| Accounts receivable | 11,685 | 9,289 | ||||||
| Inventory | (335 | ) | 1,315 | |||||
| Prepaid expenses and other assets | 608 | 1,369 | ||||||
| Other non-current assets | (293 | ) | (76 | ) | ||||
| Operating lease liabilities | (854 | ) | (785 | ) | ||||
| Accounts payable | 6,811 | 2,701 | ||||||
| Accrued liabilities | (3,126 | ) | (6,166 | ) | ||||
| Other, net | 235 | 57 | ||||||
| Net cash provided by (used in) operating activities | 7,240 | 4,198 | ||||||
| Cash flows from investing activities | ||||||||
| Purchases of available-for-sale marketable securities | (16,071 | ) | (15,090 | ) | ||||
| Sales and maturities of available-for-sale marketable securities | 11,317 | 16,739 | ||||||
| Purchases of property and equipment | (3,062 | ) | (3,543 | ) | ||||
| Net cash provided by (used in) investing activities | (7,816 | ) | (1,894 | ) | ||||
| Cash flows from financing activities | ||||||||
| Debt issuance costs | (6 | ) | — | |||||
| Payments on insurance premium financing | (466 | ) | — | |||||
| Proceeds from exercise of employee stock options | 91 | 119 | ||||||
| Taxes from withheld shares | (207 | ) | (401 | ) | ||||
| Net cash provided by (used in) financing activities | (588 | ) | (282 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | (1,164 | ) | 2,022 | |||||
| Cash and cash equivalents at beginning of period | 10,708 | 11,350 | ||||||
| Cash and cash equivalents at end of period | $ | 9,544 | $ | 13,372 | ||||
| Supplemental disclosure of cash flow information | ||||||||
| Cash paid for interest | $ | 858 | $ | 1,229 | ||||
| Noncash investing activities | ||||||||
| Unrealized (gains) losses, net on marketable securities | $ | 98 | $ | 40 | ||||
| Noncash financing activities | ||||||||
| Legal cost financing | $ | 497 | $ | 45 | ||||
| Treace Medical Concepts, Inc. Reconciliation of GAAP Net Loss to EBITDA & Adjusted EBITDA (in thousands) (unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Net loss | $ | (17,961 | ) | $ | (15,922 | ) | |
| Adjustments: | |||||||
| Interest income | (501 | ) | (841 | ) | |||
| Interest expense | 1,570 | 1,311 | |||||
| Taxes | — | — | |||||
| Depreciation & Amortization | 899 | 2,461 | |||||
| EBITDA | $ | (15,993 | ) | $ | (12,991 | ) | |
| Share-based compensation expense | 8,034 | 8,693 | |||||
| Restructuring costs1 | 204 | — | |||||
| Litigation costs2 | 2,270 | 455 | |||||
| Adjusted EBITDA | $ | (5,485 | ) | $ | (3,843 | ) | |
1 Restructuring charges primarily relate to severance payments and other post-employment benefits.
2 Litigation costs related to intellectual property lawsuits.
